INTRODUCTION {#sec1}
============

Acute kidney injury (AKI) reflects an abrupt decline in kidney function that occurs frequently among hospitalized adults and has been reported to be associated with excess risks of death, kidney disease progression and cardiovascular events.[@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8] The potential importance of AKI has been further highlighted during the coronavirus disease 2019 (COVID-19) pandemic.[@bib9]

However, there are important limitations of many existing studies examining clinical complications after AKI. These include primarily retrospective designs that are susceptible to multiple biases, lack of systematic assessment of kidney function before and after the AKI episode, use of varying definitions of AKI, lack of adjudication of potential cardiovascular events, and inclusion of study populations with limited demographic diversity. In addition, hospitalized patients, who may be at increased risk for these events, are not always compared to similar hospitalized patients without AKI. Furthermore, the limited number of existing prospective studies have primarily focused on selected populations (e.g., coronary angiography,[@bib10] cardiac surgery,[@bib11], [@bib12], [@bib13] or myocardial infarction[@bib14]) and have not examined heart failure separately with atherosclerotic cardiovascular events.

Given the global burden of AKI and the need for additional evidence-based clinical guidance, we addressed these issues by prospectively examining the association between AKI with subsequent kidney-related consequences, heart failure, major atherosclerotic cardiovascular events (MACE), and death among matched adults surviving a hospitalization with or without AKI. We hypothesized AKI would be independently associated with higher risks of each of these events in the presence or absence of pre-existing chronic kidney disease (CKD).

RESULTS {#sec2}
=======

Baseline characteristics and follow-up {#sec2.1}
--------------------------------------

We enrolled and individually matched 769 adults with AKI and 769 adults without AKI, with 39.8% having pre-existing CKD ([Figure 1](#fig1){ref-type="fig"} ). The distribution of matched pairs enrolled by center was 156 (20.3%) from Kaiser Permanente Northern California, 251 (32.6%) from Vanderbilt University, 154 (20.0%) from TRIBE-AKI, and 208 (27.1%) from the University of Washington (27.1%). Among AKI participants, 561 (73%), 111 (14%) and 97 (13%) had Stages 1, 2 and 3 AKI, respectively, with only 26 (1.7%) of AKI participants receiving acute renal replacement therapy. Furthermore, 48% of AKI episodes were of brief duration, 22% were of medium duration, 12% were of long duration, and 18% were of very long duration. Regardless of CKD status, compared with non-AKI participants, those with AKI were modestly younger, had slightly lower pre-admission eGFR, and were more likely to have prior cardiovascular disease, diabetes, receive care in an intensive care unit, be diagnosed with sepsis during the index hospitalization and have higher baseline study visit levels of plasma cystatin C and proteinuria. In contrast, there were no significant differences in Hispanic ethnicity, smoking status, or baseline study visit measures of body mass index, systolic or diastolic blood pressure ([Table 1](#tbl1){ref-type="table"} ). Among participants without pre-existing CKD, the proportion of women was lower in those with AKI, but there was no significant difference in self-reported race. In participants with pre-existing CKD, there was no significant difference in gender between groups, but those with AKI were less likely to be white ([Table 1](#tbl1){ref-type="table"}).Figure 1Assembly of matched cohort of adults surviving a hospitalization with and without acute kidney injury.Table 1Baseline characteristics of adults with and without acute kidney injury, stratified by the presence or absence of chronic kidney disease at study entry.CharacteristicNo Pre-Existing CKDPre-Existing CKDAcute Kidney Injury (N=463)No Acute Kidney Injury (N=463)P ValueAcute Kidney Injury (N=306)No Acute Kidney Injury (N=306)P ValueSerum creatinine, mg/dLPre-admission0.94 (0.20)0.87 (0.17)\<0.00011.69 (0.60)1.47 (0.48)\<0.0001Inpatient2.14 (1.71)0.90 (0.20)\<0.00012.94 (1.76)1.43 (0.44)\<0.00013-month baseline1.02 (0.47)0.86 (0.20)\<0.00011.71 (0.78)1.37 (0.50)\<0.0001Estimated GFR, ml/min/1.73 m^2^ -- mean (SD)Pre-admission83.8 (17.8)86.1 (16.1)0.00342.0 (12.1)46.0 (10.2)\<0.0001Inpatient41.6 (17.2)84.0 (17.5)\<0.000124.3 (9.6)47.7 (12.3)\<0.00013-month baseline79.8 (22.5)86.9 (17.9)\<0.000144.3 (17.3)51.2 (14.7)\<0.0001Mean (SD) age, yr60.7 (12.9)61.7 (13.1)0.0268.1 (11.2)71.1 (9.4)\<0.0001Women -- no. (%)129 (27.9)191 (41.3)\<0.0001121 (39.5)133 (43.5)0.39Race -- no. (%)0.270.02White378 (81.6)394 (85.1)229 (74.8)259 (84.6)Black65 (14.0)47 (10.1)52 (17.0)31 (10.1)Other20 (4.4)22 (4.8)25 (8.2)16 (5.3)Hispanic ethnicity -- no. (%)13 (2.8)10 (2.2)0.688 (2.6)7 (2.3)0.99Smoking status -- no. (%)0.100.48Never176 (38.0)209 (45.1)132 (43.1)117 (38.2)Former199 (43.0)188 (40.6)145 (47.4)157 (51.3)Current87 (18.8)61 (13.2)25 (8.2)29 (9.5)Unknown1 (0.2)5 (1.1)4 (1.3)3 (1.0)Prior cardiovascular disease -- no. (%)200 (43.2)147 (31.8)\<0.0001172 (56.2)146 (47.7)\<0.0001Prior diabetes mellitus -- no. (%)201 (43.4)147 (31.8)\<0.0001186 (60.8)127 (41.5)\<0.0001Treated in ICU during index admission -- no. (%)340 (73.4)307 (66.3)\<0.0001205 (67.0)166 (54.2)\<0.0001Sepsis during index admission -- no. (%)89 (19.2)14 (3.0)\<0.000129 (9.5)12 (3.9)0.0063-month baseline measurements -- mean (SD)Body mass index, kg/m^2^ - mean (SD)31.4 (8.5)30.5 (7.2)0.0732.0 (8.1)30.6 (6.8)0.07Systolic blood pressure, mmHg -- mean (SD)128 (22)126 (19)0.27129 (23)127 (20)0.36Diastolic blood pressure, mmHg -- mean (SD)73 (13)74 (13)0.4268 (14)69 (14)0.55Plasma cystatin C, mg/L - median (IQR)1.2 (1.0, 1.5)1.0 (0.9, 1.2)\<0.00012.0 (1.6, 2.6)1.7 (1.4, 1.9)\<0.0001Urine protein-to-creatinine ratio - median (IQR)0.1 (0.1, 0.2)0.1 (0.1, 0.2)0.030.2 (0.1, 0.7)0.1 (0.1, 0.3)\<0.0001

Mean (SD) follow-up was 4.5 (1.8) years overall, with mean (SD) follow-up of 4.3 (1.8) years in AKI participants and 4.4 (1.8) years and non-AKI participants. During follow-up, 82 AKI and 82 non-AKI participants withdrew from the study.

Kidney outcomes {#sec2.2}
---------------

During follow-up, CKD incidence was 4.1 per 100 person-years in AKI participants compared with 1.8 per 100 person-years in matched non-AKI adults (P\<0.0001) ([Figure 2](#fig2){ref-type="fig"} A). In participants with pre-existing CKD, the rate of those experiencing CKD progression was 2.1 per 100 person-years in AKI participants compared with 0.7 per 100 person-years in matched non-AKI participants (P\<0.0001) ([Figure 2](#fig2){ref-type="fig"}B).Figure 2Kaplan-Meier estimates of renal, major atherosclerotic cardiovascular events, heart failure events and all-cause death in patients with and without acute kidney injury, stratified by the presence or absence of pre-existing chronic kidney disease. Panel A shows results for incident chronic kidney disease. Panel B shows results for progressive chronic kidney disease. Panel C shows results for major atherosclerotic events. Panel D shows results for heart failure events. Panel E shows results for all-cause death.

In multivariable analysis among matched participants without pre-existing CKD, AKI was associated with a 3.4-fold higher adjusted rate of incident CKD (Model 1, [Table 2](#tbl2){ref-type="table"} ). Further adjustment for additional demographic characteristics, sepsis during the index admission and smoking, diabetes status and body mass index at the baseline visit strengthened the association (adjusted hazard ratio 3.98, 95%CI:2.51 to 6.31) (Model 2, [Table 2](#tbl2){ref-type="table"}). AKI was associated with a 2.3-fold higher adjusted rate of CKD progression in matched participants (Model 1, [Table 2](#tbl2){ref-type="table"}), and the association with CKD progression increased after adjustment for additional potential confounders (adjusted hazard ratio 2.37, 95%CI:1.28 to 4.39) (Model 2, [Table 2](#tbl2){ref-type="table"}). For both incident and progressive CKD, there was also a significant trend (P\<0.001 for linear trend) with more severe and longer AKI in multivariable analyses (*Supplemental Appendix 2 and 3*). In a sensitivity analysis among AKI and non-AKI participants exactly matched on each matching criteria, results were similar to the main analyses (*Supplementary Appendix 4*).Table 2Association of acute kidney injury with development of incident chronic kidney disease and progression of chronic kidney disease.Hazard Ratio (95% Confidence Interval) of AKI vs. No AKI on Kidney OutcomesNested ModelIncident Chronic Kidney DiseaseChronic Kidney Disease ProgressionModel 1: Matched\* cohort3.41 (2.35 to 4.95)2.30 (1.32 to 3.99)Model 2: Model 1 + gender; race/ethnicity; sepsis during index admission; 3-month baseline visit smoking status, diabetes status and body mass index3.98 (2.51 to 6.31)2.37 (1.28 to 4.39)[^2]

Heart failure events {#sec2.3}
--------------------

Among matched participants without prior CKD, the incidence of hospitalization for heart failure was higher in those with vs. without AKI (3.0 vs. 1.1 per 100 person-years, respectively, P\<0.001). The pattern was similar in those with pre-existing CKD, with a higher incidence in those with vs. without AKI (5.9 vs. 3.9 per 100 person-years, respectively, P=0.014) ([Figure 2](#fig2){ref-type="fig"}C).

In multivariable analysis among matched participants, AKI was associated with a nearly twofold higher adjusted rate of heart failure events (Model 1, [Table 3](#tbl3){ref-type="table"} ) that was attenuated after additional adjustment for potential confounders (adjusted hazard ratio 1.68, 95%CI:1.22 to 2.31) (Model 2, [Table 3](#tbl3){ref-type="table"}). However, further adjustment for eGFR, cystatin C and proteinuria measured at the 3-month post-discharge baseline visit markedly attenuated the association of AKI with subsequent heart failure hospitalization which was no longer significant (Model 3, [Table 3](#tbl3){ref-type="table"}). The relative strength of association was weaker in those with vs. in those without pre-existing CKD, but the patterns with multivariable adjustment were similar ([Table 3](#tbl3){ref-type="table"}).Table 3Association of acute kidney injury with subsequent heart failure, major atherosclerotic cardiovascular events and death, overall and stratified by pre-existing chronic kidney disease.Hazard Ratio (95% Confidence Interval) of AKI vs. No AKIHeart FailureMajor Atherosclerotic Cardiovascular EventDeath from Any CauseNested ModelOverallNo Pre-existing CKD\*Pre-existing CKDOverallNo Pre-existing CKDPre-existing CKDOverallNo Pre-existing CKDPre-existing CKDModel 1: Matched^†^ cohort1.83 (1.37 to 2.44)2.70 (1.73 to 4.21)1.24 (0.89 to 1.72)1.01 (0.75 to 1.34)0.95 (0.64 to 1.40)1.07 (0.73 to 1.56)1.89 (1.35 to 2.63)1.67 (1.08 to 2.58)2.13 (1.36 to 3.34)Model 2: Model 1 + gender, race/ethnicity, sepsis during index admission, 3-month baseline visit smoking status, diabetes status and body mass index1.68 (1.22 to 2.31)2.47 (1.54 to 3.96)1.14 (0.79 to 1.66)0.95 (0.70 to 1.28)0.90 (0.59 to 1.37)1.00 (0.65 to 1.52)1.78 (1.24 to 2.56)1.38 (0.85 to 2.26)2.29 (1.41 to 3.71)Model 3: Model 2 + 3-month baseline visit estimated glomerular filtration rate, plasma cystatin C and urine protein-to-creatinine ratio1.13 (0.80 to 1.61)1.48 (0.94 to 2.33)0.87 (0.55 to 1.38)1.20 (0.85 to 1.70)0.99 (0.63 to 1.55)1.46 (0.92 to 2.30)1.29 (0.84 to 1.98)1.34 (0.75 to 2.39)1.24 (0.70 to 2.18)[^3][^4]

In addition, after accounting for matching variables and potential confounders, there was a significant association of more severe AKI with heart failure hospitalization in those without pre-existing CKD (P=0.022 for linear trend) but not in those with pre-existing CKD (P=0.62 for linear trend). The association in those without pre-existing CKD was notably attenuated and no longer significant after further adjustment for baseline visit measures of kidney function and proteinuria (*Supplemental Appendix 2*). Longer AKI duration was associated with higher adjusted rate of heart failure hospitalization in a fully-adjusted model (*Supplemental Appendix 3*). In a sensitivity analysis of exactly matched AKI and non-AKI participants, results were similar to the main analysis except that there remained a twofold higher adjusted risk of heart failure events associated with AKI and no pre-existing CKD, even after additionally accounting for three-month post-discharge measures of kidney function and proteinuria (*Supplemental Appendix 4*).

Major atherosclerotic cardiovascular events {#sec2.4}
-------------------------------------------

In those without underlying CKD, the incidence of MACE was 1.5 per 100 person-years in AKI participants compared to 1.6 per 100 person-years in matched non-AKI participants (P=0.66). There was also no significant difference in MACE incidence between those with CKD with AKI vs. without AKI (3.6 vs. 3.1 per 100 person-years, respectively, P=0.64) ([Figure 2](#fig2){ref-type="fig"}D). Results were unchanged in multivariable analyses ([Table 3](#tbl3){ref-type="table"}). There was also no significant association between AKI severity and MACE (*Supplemental Appendix 2*). Results were similar to the main analysis in a sensitivity analysis among the subset of AKI and non-AKI participants that were exactly matched on all matching criteria (*Supplemental Appendix 4*).

Mortality {#sec2.5}
---------

All-cause mortality was higher in those with vs. without AKI and in the presence or absence of pre-existing CKD ([Figure 2](#fig2){ref-type="fig"}E). After accounting for matching and additional confounders, AKI was associated with a 78% higher rate of death (Model 2, [Table 3](#tbl3){ref-type="table"}) that was markedly attenuated and no longer significant after further accounting for degree of renal recovery and proteinuria status at three months post-discharge (Model 3, [Table 3](#tbl3){ref-type="table"}). Results were similar in fully-adjusted models regardless of the presence of pre-existing CKD ([Table 3](#tbl3){ref-type="table"}). There was a significant trend of more severe AKI with excess mortality that was attenuated and no longer significant after adjustment for three-month post-discharge kidney function and proteinuria, while longer AKI duration was independently associated with higher mortality (*Supplemental Appendix 2 and 3*). In sensitivity analyses in the subset of AKI and non-AKI participants that were exactly matched on all matching criteria, results were similar to the main analyses, except that AKI was independently associated with a nearly twofold higher rate of death in those with pre-existing CKD even after additional adjustment for three-month post-discharge kidney function and proteinuria (*Supplemental Appendix 4*).

DISCUSSION {#sec3}
==========

In a prospective cohort of matched hospital survivors, AKI was independently associated with higher subsequent risks of both incident CKD and progressive CKD. In the overall matched cohort, AKI was also associated with excess risks of heart failure hospitalization and all-cause death---regardless of the presence or absence of pre-existing CKD---but these associations were substantially attenuated and no longer statistically significant after accounting for residual kidney function and proteinuria measured three months after discharge. In fully-adjusted models stratified by pre-existing CKD status, we also found that AKI remained significantly associated with an excess risk of heart failure events in patients without pre-existing CKD, while there was a significantly higher risk of all-cause death in those with pre-existing CKD. However, AKI was not significantly associated with MACE, overall or in those with or without pre-existing CKD.

The ASSESS-AKI Study is unique as it represents the largest prospective cohort study of a broad population of carefully-matched adults who survived at least three months after hospital discharge to examine the association of AKI with kidney and cardiovascular events over a long follow-up period. This population is highly relevant clinically as an increasingly common scenario that physicians encounter in the outpatient setting of post-hospitalization AKI survivors. Two additional key features of ASSESS-AKI compared with previous studies are the pre-specified availability of a pre-index hospitalization serum creatinine (7 to 365 days before admission) and completion of a three-month post-discharge study visit as entry criteria. The true pre-index hospitalization "baseline" serum creatinine concentration allowed us to diagnose AKI and its severity with greater precision using currently recommended criteria.[@bib15] The systematic measurement of eGFR, plasma cystatin C and proteinuria at three months post-discharge was also critical, as we demonstrated that the overall associations of AKI with excess risks of heart failure and death were notably attenuated after accounting for residual kidney function and damage. This finding has significant clinical practice implications since evaluation of kidney function and proteinuria three months after discharge, which can be readily obtained through primary care, would yield important long-term prognostic information. Our study had several additional strengths beyond the prospective design and structured protocol among a matched cohort that helps overcome many biases that can affect retrospective studies. We had systematic, long-term follow-up measurements of post-discharge kidney function and identification and validation of heart failure events and MACE using standardized criteria. Our cohort also included a geographically diverse set of patients recruited from ICU and non-ICU hospitalized settings.

Our study also has several limitations. Information was not available on the presence and severity of proteinuria before the index hospitalization. Data were also unavailable on pre-admission eGFR slope, as well as aetiology of the AKI episode, although we note there is no generally acceptable approach to adjudicate accurately the true aetiology of AKI.[@bib16] Information on pre-admission blood pressure was also unavailable. Given our cohort was based in North American clinical centers and enriched with patients undergoing cardiac surgery or treated in an intensive care unit, our results may not fully generalize to all hospitalized patients, practice settings or geographic areas. As an observational study, we cannot prove causal relationships between an episode of AKI and subsequent clinical outcomes, as we cannot rule out residual or unmeasured confounding.

The population of survivors of AKI is growing in parallel with the number of patients experiencing sepsis or cardiovascular diseases, including heart failure.[@bib17] ^,^ [@bib18] Our findings that suggest AKI, even its mildest form, may contribute to long-term adverse outcomes have important implications.[@bib19], [@bib20], [@bib21] While previous studies have examined the association of AKI on kidney and cardiac complications in hospitalized patients, many suffer from several limitations. Nearly all studies were retrospective in design with their accompanying biases, and several relied only on administrative codes to assign AKI status rather than objective pre-admission and in-hospital serum creatinine results. Our study materially expands on a recent prospective study of 968 adults undergoing cardiac surgery which found that AKI was associated with a higher adjusted rate of the composite outcome of death or hospitalization for acute coronary syndrome, heart failure or receipt of coronary revascularization.[@bib22]

Mechanisms by which AKI drives development and progression of CKD, as well as excess heart failure complications, are not fully elucidated.[@bib23] AKI is associated with increased levels of inflammatory cytokines,[@bib24] endothelial dysfunction,[@bib25] dysregulation in mineral metabolism,[@bib26] ^,^ [@bib27] and myocardial damage.[@bib28] Yet, shared risk factors between AKI, CKD, and cardiovascular disease (e.g., age, diabetes, hypertension) and lack of mechanistic studies have raised some skepticism about a causal relationship between AKI and future adverse outcomes.[@bib23] One potential explanation is that the kidney plays a critical role in sodium handling and subsequent volume status and blood pressure control. Tubular injury sustained during AKI, especially in severe forms, could lead to impaired natriuresis that can predispose to subclinical vascular congestion during high sodium intake.[@bib23] ^,^ [@bib29], [@bib30], [@bib31] This would, in turn, result in subtle tubular dysfunction whose effects on vulnerable kidneys may accumulate over time leading to a vicious cycle of recurrent AKI episodes, heart failure and progressive CKD.

In summary, we found that AKI independently associated with higher rates of incident and progressive CKD, as well as subsequent heart failure events and death among survivors of a recent hospitalization. However, after additionally accounting for degree of renal recovery and proteinuria status three months after discharge, the associations of AKI with heart failure and death were not significant. More severe and longer AKI duration may also be associated with worse clinical outcomes. Our study provides new data to support systematically evaluating level of kidney function recovery and proteinuria three months after an episode of AKI to provide relevant prognostic information that may help guide clinical decision-making. Furthermore, definitive randomized trial evidence is needed to determine if strategies to prevent AKI or interventions early in the course of AKI can reduce the risks of future adverse renal and cardiovascular outcomes.[@bib23]

METHODS {#sec4}
=======

Study Population {#sec4.1}
----------------

The ASSESS-AKI Study, sponsored by the National Institute of Diabetes, Digestive and Kidney Diseases of the U.S. National Institutes of Health, is a prospective, matched cohort study of hospitalized persons who did or did not experience an episode of AKI and survived to complete an in-person baseline study visit three months after discharge. Details of the design and methods have been previously described.[@bib32] Briefly, 769 hospitalized adults who experienced an episode of AKI were enrolled between December 2009-February 2015 from four North American clinical centers involving various hospital settings (general medical and surgical wards, intensive care unit \[ICU\] and post-cardiac surgery), with eligibility confirmed at the baseline visit three months after discharge. Briefly, Kaiser Permanente Northern California recruited participants hospitalized in medical and surgical wards as well as ICUs at four Kaiser Permanente medical centers (Oakland, Walnut Creek, Hayward and San Francisco, CA). Vanderbilt University recruited participants from the Validation of Acute Lung Injury Biomarkers for Diagnosis (VALID) Study of critically ill patients[@bib33] as well as patients hospitalized at Vanderbilt Medical Center (Nashville, TN) in ICU and medical and surgical ward settings. TRIBE-AKI investigators enrolled adult participants in the TRIBE-AKI (Translational Research Investigating Biomarker Endpoints for Acute Kidney Injury) Consortium[@bib34] during pre-operative evaluation for cardiac surgery at Yale University (New Haven, CT) and London Health Sciences Center (Ontario, Canada). The University of Washington enrolled participants from the ICU as well as medical and surgical wards at Harborview Medical Center (Seattle, WA).

AKI during the index hospitalization was defined using Kidney Disease: Improving Global Outcomes (KDIGO) criteria[@bib15] based on an increase of ≥50% or ≥0.3 mg/dL in serum creatinine concentration above an outpatient, non-emergency department baseline value within 7 to 365 days before the index admission. During the same period, a matched sample of 769 hospitalized adults without AKI at the same sites were enrolled. We aimed to have a wide range of AKI severity represented, with targeted enrollment of one third of participants having stage 2 or 3 AKI.[@bib15] Patients were individually matched on clinical research center and pre-admission CKD status, with additional matching to reduce confounding using an integrated, weighted priority score (0 to 100) based on prior cardiovascular disease (30 points), prior diabetes mellitus (25 points), pre-admission level of estimated glomerular filtration rate (eGFR) category (15-29, 30-44, 45-59, 60-89, 90-150 mL/min/1.73m^2^) using the CKD-EPI equation[@bib35] (20 points), age category (18-39, 40-49, 50-59, 60-69, 70-79, 80-89 years)(15 points), and receiving treatment within an intensive care unit during the index hospitalization (10 points). Detailed inclusion and exclusion criteria are described in the protocol[@bib32] and *Supplementary Appendix 1*. Briefly, the main inclusion criteria included age 18-89 years and having a baseline outpatient, non-emergency department serum creatinine value within 365 days before enrollment. Major exclusion criteria included inability to provide consent; acute glomerulonephritis; hepatorenal syndrome; multiple myeloma, metastatic or actively treated malignancy; significant urinary tract obstruction; severe heart failure; death, receiving chronic dialysis, kidney or other transplant before the three-month post-discharge baseline visit; pregnant or breastfeeding; enrolled in an interventional study at the baseline study visit; or predicted survival of 12 months of less by a study physician.

The study was carried out in a clinical research facility. All the study participants were volunteers. Neither the study participants nor the public were involved in the development of research questions, study design and measures, or assessment of the time required to participate in the research. The study was approved by institutional review boards of the participating institutions, and written informed consent was obtained from participants. Results of the study will be shared with study participants.

Study Visits {#sec4.2}
------------

At the three-month post-discharge baseline visit, we obtained information on sociodemographic characteristics; nephrotoxic exposures and complications occurring during the index hospitalization; cardiovascular, renal and other medical history; tobacco use; and prescription and over-the-counter medication use.[@bib32] In addition, height, weight, blood pressure and heart rate were measured using standardized methods.[@bib32] Blood samples for DNA, sera and plasma were collected; a urine dipstick proteinuria test performed; and 12-lead electrocardiogram was obtained using standardized methods.

A follow-up visit was conducted 12 months after the index hospitalization and annually thereafter (with determination of eGFR), with interim phone contacts at 6-month intervals.[@bib32] Medical history, including interim hospitalizations, and medication use were updated at each contact.

Follow-up and Outcome Ascertainment {#sec4.3}
-----------------------------------

Follow-up occurred through November 2018, with censoring due to withdrawal or end of study follow-up. Vital status was updated at each study contact and through medical records review. Kidney and cardiovascular events were *a priori* considered primary outcomes.

Kidney events included incident CKD and CKD progression. Incident CKD among participants without pre-existing CKD at the index hospitalization was defined as the combination of ≥25% reduction in eGFR (compared with pre-index admission eGFR) and achieving CKD Stage 3 or worse.[@bib36] In participants with pre-existing CKD at the index hospitalization (defined as pre-admission eGFR \<60 ml/min/1.73 m^2^), CKD progression was defined as ≥50% reduction in eGFR compared with baseline, reaching CKD Stage 5 or receiving renal replacement therapy (chronic dialysis or kidney transplant).[@bib36]

We ascertained potential heart failure events and MACE based on participant self-report, and by periodic searches of electronic medical records. For all hospitalizations, we initially obtained information on *International Classification of Diseases, Ninth or Tenth Edition* diagnostic codes for heart failure and MACE, including myocardial infarction, ischemic stroke and peripheral artery disease (codes available on request).[@bib32] For hospitalizations without a qualifying code, the discharge summary was reviewed by a study investigator to ensure no heart failure events or MACE were missed. The event adjudication committee, comprised of trained physicians from each clinical center, centrally and locally adjudicated potential cardiovascular events based on a review of medical records using Framingham Heart Study clinical criteria[@bib37] for heart failure and standardized criteria[@bib38] ^,^ [@bib39] for MACE.

Vital status was captured through protocol-driven phone-based surveillance complemented by proxy reporting by participants' contacts, information from sites' electronic medical record systems, and death certificate data, as available at each participating center.

Covariates {#sec5}
==========

Demographic characteristics included age, gender and self-reported race (white, black, other) and Hispanic ethnicity. We recorded self-reported tobacco use and prior cardiovascular disease (i.e., heart failure, myocardial infarction, stroke or peripheral artery disease). Hypertension was based on self-report combined with receipt of antihypertensive agents, or having a study visit systolic blood pressure \>140 mmHg and/or diastolic blood pressure \>90 mmHg. Diabetes mellitus was based on self-report, receipt of antidiabetic agents or glycosylated hemoglobin ≥6.5%. At the baseline visit occurring at 90 days post-discharge, we measured serum creatinine using an IDMS-traceable enzymatic assay (Roche Diagnostics, Indianapolis, IN), plasma cystatin C standardized against the international calibrator standard ERMDA471/IFCC (Gentian, Moss, Norway), and a random spot urine protein-to-creatinine ratio using a turbidimetric method (Roche, Indianapolis, IN).

Statistical approach {#sec5.1}
--------------------

Analyses were conducted using SAS software, version 9.4 (Cary, NC). Characteristics were compared between matched AKI and non-AKI participants using paired t tests or Wilcoxon signed-rank tests for continuous variables and McNemar's tests for categorical variables. Rates of each outcome (per 100 person-years) with associated 95% confidence limits were calculated for AKI and non-AKI participants, and cumulative incidence curves compared using a log-rank test.

For each outcome, after confirming no violation of the proportional hazards assumption by examining log-log-survival curves, we performed nested Fine-Gray subdistribution hazard analyses[@bib40] accounting for individual matching and competing risk of death, with additional incremental adjustment for variables not included in the matching criteria that have been previously reported or hypothesized to be risk factors for kidney and cardiovascular events, or differing between AKI and non-AKI participants at the baseline study visit. Based on an *a priori* hypothesis, pre-specified overall and stratified analyses were performed to evaluate for a potential interaction between an episode of AKI and pre-existing CKD status.[@bib32] For cardiovascular and death outcomes, the final model additionally adjusted for three-month post-discharge measures of kidney function and proteinuria based on *a priori* hypotheses that levels of residual kidney function and damage may explain, at least in part, any observed excess risks for these clinical outcomes after an episode of AKI. Models were performed overall and stratified by pre-existing CKD status, as appropriate. Because outcomes were time-to-event with right-censoring due to death, study withdrawal or end of study follow-up, we did not impose any procedure to account for potential missingness in the outcomes.

We separately examined the association of severity of the index AKI episode with outcomes of interest by modeling KDIGO stage of AKI (1, 2 or 3) as a linear term. We used a similar approach to separately examine the association of AKI episode duration (non-AKI, AKI ≤1 day \[brief\], 1 day \< AKI duration ≤ 3 days \[medium\], 3 days \< AKI duration ≤ 6 days \[long\], AKI duration \> 6 days \[very long\]). Because our matching algorithm did not result in an exact match on all criteria in the 769 pairs of AKI and non-AKI participants, we also conducted sensitivity analyses among 1375 patients placed within 328 strata who were exactly matched on all individual matching criteria within each stratum.
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